1.59
+0.045(+2.92%)
Currency In USD
| Previous Close | 1.54 |
| Open | 1.48 |
| Day High | 1.6 |
| Day Low | 1.39 |
| 52-Week High | 2.74 |
| 52-Week Low | 0.36 |
| Volume | 2.84M |
| Average Volume | 7.74M |
| Market Cap | 210.38M |
| PE | -3.52 |
| EPS | -0.45 |
| Moving Average 50 Days | 1.48 |
| Moving Average 200 Days | 0.98 |
| Change | 0.05 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $75.91 as of November 08, 2025 at a share price of $1.585. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $435.44 as of November 08, 2025 at a share price of $1.585.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
GlobeNewswire Inc.
Nov 03, 2025 9:01 PM GMT
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday,
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
GlobeNewswire Inc.
Oct 28, 2025 11:01 AM GMT
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live webcast to present an overview of the company’s REVOLUTION clinical program, Invivyd’s development program for VYD2311,
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
GlobeNewswire Inc.
Oct 06, 2025 11:01 AM GMT
The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025; top-line data anticipated mid-2026DECLARATIO